Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-α in vitro and in vivo

Immunopharmacology

Volumn 36, Issue 1, 1997, Pages 49-55

  Fukuzawa, Masamitsu ^a   Satoh, Jo ^a   Sagara, Mikio ^a   Muto, Gen ^a   Muto, Yoshiko ^a   Nishimura, Sachiko ^a   Miyaguchi, Shuichi ^a   Qiang, Xiao Ling ^a   Sakata, Yoshiyuki ^a   Nakazawa, Tetsuya ^a   Ikehata, Fumiko ^a   Ohta, Setsu ^a   Toyota, Takayoshi ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ACE inhibitor; captopril; cilazapril; delapril; tumor necrosis factor

Indexed keywords

CAPTOPRIL; CILAZAPRIL; DELAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; INSULIN RESISTANCE; MOUSE; NONHUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CAPTOPRIL; DRUG INTERACTIONS; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED BALB C; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031002708     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(96)00160-9     Document Type: Article

References (30)

1. Berne C, Pollare T, Lithell H. Effects of anti-hypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care 1991; 14 (Suppl. 4): 39-47.
2. Beutler B, Cerami A. Cachectin: More than a tumor necrosis factor. N Engl J Med 1987; 316: 379-385.
3. Chaudri G, Clark IA. Reactive oxygen species facilitate the in vitro and in vivo lipopolysaccharide-induced release of tumor necrosis factor. J Immunol 1989; 143: 1290-1294.
4. Crofton JT, Share L, Horovitz ZP. The effect of SQ14.225 on systolic blood pressure and urinary excretion of vasopressin in the developing spontaneously hypertensive rat. Hypertension 1979; 1: 462-467.
5. Eisenhut T, Shinha B, Wolfers EG, Semmler J, Siess W, Endres S. Prostacyclin analogs suppress the synthesis of tumor necrosis factor-α in LPS-stimulated human peripheral blood mononuclear cells. Immunopharmacology 1993; 26: 259-264.
6. Feinsteine R, Kanety H, Papa MZ, Lunenfeld B, Karasik A. Tumor necrosis factor-a suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 1993; 268: 26055-26058.
7. Gavras H, Faxon DP, Berkoben J, Brunner HR, Ryan TJ. Angiotensin converting enzyme inhibition in patients with congestive heart failure. Circulation 1978; 58: 770-776.
8. Gearing AJH, Becket P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL. Processing of tumor necrosis factor-α precursor by metalloproteases. Nature 1994; 370: 555-557.
9. Hefti F, Fischli W, Gerold M. Cilazapril prevents hypertension in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1989; 8: 641-648.
10. Hotamisligil GS, Shargil NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: Direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
11. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: A key component of the obesity-diabetes link. Diabetes 1994; 43: 1271-1278.
12. Hwang DR, Eckelman WC, Mathias CJ, Petrillo EW, Lloyd J, Welch MJ. Positron-labeled angiotensin converting enzyme (ACE) inhibitor: Fluorine-18-fluorocaptopril. Probing the ACE activity in vivo by positron emission tomography. J Nucl Med 1991; 32: 1730-1737.
13. Inada Y, Tanabe M, Shibouta Y, Kawazoe K, Nishikawa K, Kikuchi S. Antihypertensive action of a non-sulfhydryl angiotensin converting enzyme inhibitor (CV-3317) in various hypertensive models. Jpn J Pharmacol 1986; 42: 1-8.
14. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in sever chronic heart failure. N Engl J Med 1990; 323: 236-241.
15. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47: 25-49.
16. Maini RN, Elliot M, Brennan FM, Williams RO, Feldmann M. Targeting TNF alpha for the therapy of rheumatoid arthritis. Clin Exp Rheumatol 1994; 12 (Suppl. 11): S63-66.
17. Martin MFR, Surrall KE, McKenna F, Dixon JS, Bird HA, Write V. Captopril: A new treatment for rheumatoid arthritis? Lancet 1984; 1: 1325-1327.
18. Matsui S, Matsumori A, Sasayama S. Vesnarinone prolongs survival and reduces lethality in a murine model of lethal endotoxemia Life Sci 1994; 55: 1735-1741.
19. Matsumori A, Shioi T, Yamada T, Matui S, Sasayama S. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation 1994; 89: 955-958.
20. McGeehan GM, Becherer JD, Bast RCJr, Boyer CM, Champion B, Colly KM, Conway JG, Furdon P, Karp S, Kidao S. Regulation of tumor necrosis factor-α processing by metalloprotease inhibitor. Nature 1994; 370: 558-561.
21. Salvetti A. Newer ACE inhibitors. A look at the future. Drugs 1990; 9: 800-828.
22. Satoh J, Seino H, Abo T, Tanaka S, Shintani S, Ohta S, Tamura K, Sawai T, Nobunaga T, Ohteki T, Kumagai K, Toyota T. Recombinant human tumor necrosis factor a suppresses autoimmune diabetes in nonobese diabetic mice. J Clin Invest 1989; 84: 1345-1348.
23. Schindler R, Dinarello CA, Koch KM. Angiotensin-converting-enzyme inhibitors suppress synthesis of tumour necrosis factor and interleukin 1 by human peripheral blood mononuclear cells. Cytokine 7: 526-533, 1995.
24. Shindo K, Baker RJ, Munafo DA, Bigby TD. Captopril inhibits neutrophil synthesis of leukotrien B4 in vitro and in vivo. J Immunol 1994; 153: 5750-5759.
25. Suzuki S, Sato H, Shimada H. Comparative free radical scavenging action of angiotensin converting enzyme inhibitors with and without sulfhydryl radical. Pharmacology 1993; 47: 61-65.
26. Takeyama K, Minato H, Ikeno A, Hosoki K, Kadokawa T. Antihypertensive mechanism of alacepril: Effect on norepinephrine-induced vasoconstrictive response in vitro and in vivo. Arzneim Forsch Drug Res 1986; 36: 74-77.
27. Tannenbaum CS, Hamilton TA. Lipopolysaccharide-induced gene expression in murine peritoneal macrophages is selectively suppressed by agents that elevate intracellular cAMP. J Immunol 1989; 142: 1247-1280.
28. Unger T, Moursi M, Ganten D, Hermann K, Lang RE. Antihypertensive action of the converting enzyme inhibitor perindopril (S9490-3) in spontaneously hypertensive rats: Comparison with enalapril (MK421) and ramipril (Hoe498), J Cardiovasc Pharmacol 1986; 8: 276-285.
29. van Wijngaarden J, Tio RA, van Gilst WH, de Graeff PA, de Langen CD, Wesseling H. Coronary vasodilation induced by captopril and zofenoprilat: Evidence for a prostaglandin-independent mechanism. Arch Pharmacol 1991; 343: 491-495.
30. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 1993; 92: 2303-2312.